IRIS
GALEAZZI, MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.121
EU - Europa 24.616
AS - Asia 4.216
AF - Africa 87
SA - Sud America 61
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 27
AN - Antartide 1
Totale 57.162
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.047
GB - Regno Unito 9.053
IE - Irlanda 3.645
CN - Cina 3.071
UA - Ucraina 2.733
SE - Svezia 2.034
IT - Italia 1.687
RU - Federazione Russa 1.535
DE - Germania 1.494
FR - Francia 1.325
SG - Singapore 765
FI - Finlandia 691
ES - Italia 106
VN - Vietnam 92
BE - Belgio 81
TR - Turchia 81
IN - India 62
CI - Costa d'Avorio 58
CA - Canada 56
CZ - Repubblica Ceca 48
NL - Olanda 39
BR - Brasile 34
AU - Australia 29
PL - Polonia 28
EU - Europa 25
KR - Corea 21
IR - Iran 20
GR - Grecia 15
HK - Hong Kong 15
CH - Svizzera 14
AT - Austria 12
JP - Giappone 11
BG - Bulgaria 10
DK - Danimarca 10
RO - Romania 9
IL - Israele 8
ID - Indonesia 7
MA - Marocco 7
MY - Malesia 7
ZA - Sudafrica 7
AZ - Azerbaigian 6
EG - Egitto 6
MX - Messico 6
PH - Filippine 6
SK - Slovacchia (Repubblica Slovacca) 6
AR - Argentina 5
HU - Ungheria 5
KZ - Kazakistan 5
LU - Lussemburgo 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
BD - Bangladesh 4
CL - Cile 4
CO - Colombia 4
HR - Croazia 4
LT - Lituania 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
PE - Perù 4
AM - Armenia 3
BO - Bolivia 3
CY - Cipro 3
DZ - Algeria 3
EC - Ecuador 3
IM - Isola di Man 3
LA - Repubblica Popolare Democratica del Laos 3
MK - Macedonia 3
PA - Panama 3
PK - Pakistan 3
PY - Paraguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CR - Costa Rica 2
CU - Cuba 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
KE - Kenya 2
KH - Cambogia 2
KW - Kuwait 2
NP - Nepal 2
PT - Portogallo 2
RS - Serbia 2
BY - Bielorussia 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GL - Groenlandia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HN - Honduras 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MD - Moldavia 1
NG - Nigeria 1
NO - Norvegia 1
SL - Sierra Leone 1
SM - San Marino 1
TH - Thailandia 1
Totale 57.160
Salva come PNG Salva come JPEG
Città #
Southend 8.589
Fairfield 3.997
Dublin 3.606
Menlo Park 2.428
Chandler 2.262
Jacksonville 2.232
Ashburn 2.228
Woodbridge 1.904
Houston 1.847
Wilmington 1.543
Seattle 1.479
Cambridge 1.342
Ann Arbor 1.163
Nanjing 757
Princeton 735
Beijing 661
Siena 529
Singapore 486
Boardman 336
San Mateo 316
New York 286
Helsinki 265
Nanchang 249
San Diego 247
Dearborn 180
Shenyang 175
Moscow 167
Düsseldorf 159
Hebei 127
Shanghai 125
Tianjin 122
Changsha 115
Venezia 107
Jiaxing 105
Málaga 96
Dong Ket 90
Kunming 88
Lancaster 86
Brussels 76
Jinan 74
Norwalk 66
Munich 64
Rome 63
Abidjan 58
Izmir 58
London 56
Washington 56
Saint Petersburg 53
Milan 51
Guangzhou 50
Mestre 50
Zhengzhou 50
Ningbo 48
San Francisco 47
Hangzhou 45
Falls Church 44
Redwood City 42
Changchun 41
Los Angeles 39
Toronto 39
Taizhou 35
Florence 34
Brno 25
Hefei 25
Lanzhou 25
Tappahannock 25
Fremont 23
Santa Clara 20
Bologna 19
Fuzhou 19
Frankfurt am Main 18
Kraków 18
Olomouc 18
Hounslow 17
Kiev 16
Asciano 14
Paris 14
Chiswick 13
Pisa 13
Chicago 12
Kilburn 12
Phoenix 12
Prescot 12
São Paulo 12
Amsterdam 11
Edinburgh 11
Philadelphia 11
Padova 10
Vienna 10
Auburn Hills 9
Central 9
Dallas 9
Groningen 9
Hanover 9
Messina 9
Napoli 9
Perugia 9
Bari 8
Haikou 8
Melbourne 8
Totale 42.999
Salva come PNG Salva come JPEG
Nome #
null 412
Comparison of combination therapies in the treatment of rheumatoid arthritis :leflunomide-anti-TNF-alfa versus methotrexate-anti-TNF-alfa 362
UNIREUMA -REUMATOLOGIA PER STUDENTI E MEDICI DI MEDICINA GENERALE I EDIZIONE 338
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study 256
Obesity reduces the response rate to anti TNFα in rheumatoidarthritis. an approach to a personalized medicine 247
Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis 245
Arrhythmogenicity of Anti-Ro/SSA antibodies in patients with torsades de pointes 237
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry 237
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis 232
Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system 232
Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung 228
Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. 220
Livello sierico della COMP (Cartilage Oligomeric Matrix Protein): Uso potenziale come marker di progressione del danno articolare nei pazienti con "Early Rheumatoid Arthritis" 217
Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project" 216
The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF-α 212
Antiarrhythmic potential of anti-cytokine therapy in rheumatoid arthritis: Tocilizumab reduces QTc interval by controlling systemic inflammation. 212
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 211
Validation of an Italian version of the functional index for hand osteoarthritis (FIHOA) 207
Eosinophilia-associated muscle disorders:an immunohistological study with tissue localisation of major basic protein in distinct clinicopathological forms 207
Bone mineral density in patients with systemic sclerosis. 202
Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review 202
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies 201
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study 200
One-year follow-up of mud-bath therapy in patients with bilateral knee osteoarthritis: a randomized, single-blind controlled trial 200
Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature 200
Alkaptonuria is a novel human secondary amyloidogenic disease 198
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 198
Expression of RXFP1 in skin of scleroderma patients and control subjects 197
Ultrasonography and magnetic resonance imaging of heel fat pad inflammatory-oedematous lesions in rheumatoid arthritis 195
Change perspective to increase diagnostic accuracy of ultrasonography in calcium pyrophosphate dehydrate deposition disease! A new approach: The axial scan of the meniscus 195
Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults 193
The Immunogenetics of the Antiphospholipid Syndrome, Anticardiolipin Antibodies, and Lupus Anticoagulant 191
Circulating levels of adiponectin, resistin, and visfatin after mud-bath therapy in patients with bilateral knee osteoarthritis 190
Weekly oral alendronate in mevalonate kinase deficiency 189
Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study 189
FRI0501 Ultrasound versus synovial fluid analysis for the diagnosis of calcium pyrophosphate dihydrate deposition disease: preliminary results 187
Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet’s Disease 186
High levels of maternal serum IL-17 and activin A in pregnant women affected by systemic lupus erythematosus 186
Colchicine myopathy and neuromyopathy: two cases with different characteristics 184
Deltoideal acromial enthesopathy in ankylosing spondylitis and in spondylarthropathies: comment on the article by Lambert et al. 183
SAT0312 Ultrasound Reliability in the Diagnosis of Calcium Pyrophosphate Deposition Disease: Agreement Between Observers and Main Causes of Discordance 183
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis 182
A "new" technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography 181
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 181
SAT0564 Articular Involvement in Behçet Disease: An Ultrasonographic Study 180
The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease 180
Anti-cofactor autoantibodies in systemic lupus erythematosus: prevalence, clinical and HLA class II associations 179
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders 178
The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy 178
Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus 176
Anti-Ro/SSA-associated corrected QT interval prolongation in adults: the role of antibody level and specificity 176
Increased serum leptin and visfatin levels in patients with diffuse idiopathic skeletal hyperostosis: a comparative study 176
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab 176
Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection 175
Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis 174
Statins and the joint: multiple targets for a global protection? 173
Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis 171
FRI0533 Ultrasonographic Features of Joints and Entheses in Healty Children 170
Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series 170
AB1308 Prevalence of baker’s CYST in patients with chronic gonalgia and relationship with major non inflammatory diseases 170
Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema 170
Working the endless puzzle of hereditary autoinflammatory disorders. 169
Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients 168
Hydrostatic pressure regulates MicroRNA expression levels in osteoarthritic chondrocyte cultures via the Wnt/β-catenin pathway 168
Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes 168
SAT0542 The Prevalence of Calcium Pyrophosphate Deposits at Ultrasound Examination: Retrospective Analysis in A Cohort of Patients 167
AB0969 Accuracy of blind intra-articular injections in patients with osteoarthritis of the knee. An ultrasonography controlled study 167
High frequency of psoriasis in relatives is associated with early onset in an Italian multiple sclerosis cohort 167
Granulomatosis with polyangiitis and intravenous immunoglobulins: A case series and review of the literature 166
Viral genotype and HLA class II alleles influence on extra-hepatic manifestations of chronic HCV infection 166
Absence of anti-cyclic citrullinated peptide antibodies in erosive osteoarthritis: further serological evidence of the disease as a subset of osteoarthritis 165
Sindrome di Churg-Strauss e gravidanza efficacia del trattamento con immunoglobuline endovena 164
AB0535 Effects of tocilizumab on bone density and metabolism in patients with active rheumatoid arthritis 164
Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature 164
SAT0315 Calcium Pyrophosphate Dihydrate Deposition Disease: A Proposal of New Ultrasonographic Criteria for CPP Identification in the Joints 163
Relationship between serum comp levels and serological markers of disease activity in rheumatoid arthritis patients treated with anti-tnf drugs. A study of the best way to manage indicators of response to therapy 162
SAT0510 Ultrasound versus Synovial Fluid Analysis for the Diagnosis of Calcium Pyrophosphate Dihydrate Deposition Disease: is IT Cppd? Ask Us! 162
Could oxidative stress regulate the expression of microRNA-146a and microRNA-34a in human osteoarthritic chondrocyte cultures? 162
Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease: ultrasonographic criteria proposed. 161
Untangling the Web of Systemic Autoinflammatory Diseases 161
SAT0530 The Useful of us in Diagnosis of Carpal Tunnel Syndrome in Diabetics: a Proposal for New Reference Values 161
Can hybrid hyaluronic acid represent a valid approach to treat rizoarthrosis? A retrospective comparative study 161
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683 161
Autoinflammatory disorders and patients with isolated serosal involvement. 160
Connective tissue diseases and cardiac rhythm disorders: an overview 160
Efficacy and Safety of Adalimumab in Behçet’s disease related uveitis: a multicenter retrospective observational study 159
Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease 159
Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis 159
A whitish-creamysynovial fluid. 158
Fasitibant prevents the bradykinin andinterleukin 1β synergism on prostaglandin E(2) release and cyclooxygenase 2expression in human fibroblast-like synoviocytes 158
Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome 158
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 158
Comparison of frequency of complex ventricular arrhythmias in patients with positive versus negative anti-Ro/SSA and connective tissue disease 155
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register 155
Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA positive connective tissue diseases 154
Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis 154
Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy 154
Short- and long-term effects of spa therapy in knee osteoarthritis 153
The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study 153
First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). 152
Totale 18.769
Salva come PNG Salva come JPEG
Categoria #
all - tutte 170.215
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 170.215
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.520 0 0 0 0 740 986 955 1.566 966 1.124 448 735
2020/20217.859 397 940 195 776 357 1.120 274 1.245 734 588 634 599
2021/20226.301 532 768 428 492 430 157 258 244 441 737 589 1.225
2022/20238.041 535 580 1.077 1.189 872 1.655 108 630 835 164 256 140
2023/20245.287 232 130 441 299 188 1.553 1.757 142 24 61 71 389
2024/20252.516 229 609 859 616 203 0 0 0 0 0 0 0
Totale 57.726